Abstract: A cathodoluminescence detection system is provided, including a collection optic collecting light radiation coming from a sample illuminated by a charged particle beam and sending the light radiation to an analyzer, a positioner for the collection optic; the positioner including several translation components of the collection optic. Each translation component effects the translation of the collection optic in one dimension of space so that the translation components effect the translation of the collection optic in several dimensions of space.

Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.

Abstract: A method for turning off routers, operating according to a link-state protocol, in a communications network, said network linking a plurality of devices, said method being executed simultaneously over a plurality of routers of the network, includes: a step of initializing; a step of monitoring verifying a list of predefined conditions to be met to allow the turning off of the router; a step of waiting; a step of turning off, including the transmission of a message destined for other routers executing said method to signal the turning off of said router to them; the waiting step being carried out before the turning-off step, the turning-off step being carried out only if no turning-off message originating from other routers is received during the waiting step, if a turning-off message coming from other routers is received during the waiting step then the return to the monitoring step.

Abstract: The present invention relates to a method and a device for direct, non-deformed one-shot measurement of the transient birefringence induced in an optical medium by a perturbation lying within the terahertz frequency range. The aim of the present invention is to alleviate the drawbacks of the prior art by providing a one-shot measurement method and a one-shot measurement device, these being based on the spectral encoding/decoding principle, which are compatible with all short pulse (UV-NIR) laser sources. In this regard, the invention provides a one-shot method for measuring the transient birefringence induced in an optical medium (12) by at least one terahertz perturbation (6), the method including a step of transmitting and spectrally encoding a pulsed optical signal (2).

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: An oscillator is provided including a nanopillar and current injector for injecting a power supply current through the nanopillar, the nanopillar including at least one pattern including first and second layers made from a ferromagnetic material separated from each other by an intermediate layer made from a non-magnetic material. Each of the first and second ferromagnetic layers is prepared such that its remanent magnetic configuration corresponds to a vortex configuration and the polarity of the vortex core of the first layer is opposite the polarity of the vortex core of the second layer. The intermediate layer can allow repellant magnetic coupling between the two vortices of the first and second layers, for a zero intensity of the power supply current and a zero amplitude of the outside magnetic field.

Abstract: A method for hard surface deposition on aluminium metal parts of a turbine engine using MIG welding equipment which includes a pulsed current generator and pulsed filler metal wire feed, wherein the deposition is achieved using a filler metal wire whose composition is of the same nature as the composition of the aluminium alloy of the part to undergo hard surface deposition, with the pulsed metal wire feed and speed of deposition on the metal part of the turbine engine being adapted to carry out deposition without hot fissuring.

Abstract: Described is the use of a mutation of at least one amino acid in the immunosuppressive domain of a HIV or SIV accessory protein, for modulating the immunosuppressive property of the protein.

Abstract: The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.

Abstract: A component, device and improved electro-optical modulation system for increasing compactness, favoring the adaptation of optical and electrical waves, and a method of fabrication. Such a component exhibits a waveguide architecture devised so that the length of the path followed by the luminous flux exhibits, with the length of the path traversed by the electrical control signal, a determined difference for decreasing or compensating for the difference in the speeds of propagation of the luminous flux and of the electrical signal. In particular, the modulation zone includes a path of the luminous flux winding around itself and successively crossing at least two indentations emanating from at least two of these control elements. It thus exhibits a length greater than that traversed by the electrical signal, for example between a first and a second region of interaction between this control signal and this luminous flux.

Abstract: The invention relates to a method of implementing a ferroelectric tunnel junction, said junction comprising to films each forming an electrode-type conductive element, and separated by a film forming a ferroelectric element acting as the tunnel barrier, said ferroelectric element being able to possess a remanent polarization.

Abstract: The invention relates to a method for manufacturing a microfluidic chip, wherein said method comprises the steps of: providing a plate combined with a layer of inorganic silica gel of formula: (HsiO3/2)2n where n is an integer, and providing a lid; chemically activating the layer of silica gel and the lid, in order to make the layer of gel and the lid hydrophilic; mechanically combining the layer of gel and the lid to form a chip, such that the layer of gel forms an intermediate layer between the plate and the lid; annealing the chip, such that the layer of silica gel transforms into an intermediate layer made up of a SiO2 matrix for rigidly securing the plate to the lid. The invention also relates to a related chip and plate.

Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating cancer. More specifically, the invention relates to a polypeptide isolated from Brevibacterium aurantiacum that shows methionine gamma-lyase and homocysteinase activities. The present invention also relates to the use of such a polypeptide for the treatment of cancer.

Abstract: The invention relates to a self-balancing human transporter comprising a platform (1) flanked by two wheels (10) and equipped with a holding and driving stick (7) and a gyroscopic stabilization device acting on motors (14) that drive the wheels, each of the wheels comprising a rim (12) which collaborates with bearings (7) borne by respective crescent-shaped mounts (5) each of which extends essentially facing the associated rim and which support the associated drive motor so that this motor drives the corresponding wheel by acting on the rim, the mounts being fixed to the sides of the platform.

Abstract: The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample.

Abstract: The present invention relates to compounds of formula (I) below: for which: —X represents a hydrogen atom, a halogen atom, a group NO2 or NH2, —R0 represents H or —CH2—C?CH, and —R1 and R2 each represent, independently of one another, a hydrogen atom; a saturated or unsaturated, linear or branched hydrocarbon-based chain comprising from 1 to 10 carbon atoms; or an optionally substituted aryl group, and also the pharmaceutically acceptable salts thereof, the stereoisomers thereof or mixtures of stereoisomers thereof in any proportion, in particular for use thereof as a medicament, in particular in the treatment or prevention of neurodegenerative diseases, and also the processes for the preparation thereof and the pharmaceutical compositions comprising same.

Abstract: The present invention proposes a method for generating cyan fluorescent proteins which have reduced pH sensitivity, in particular acid-pH sensitivity.